Thyrocare Technologies Gelecekteki Büyüme

Future kriter kontrolleri 5/6

Thyrocare Technologies kazanç ve gelirin sırasıyla yıllık 26.9% ve 16.3% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 27.2% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde 25.3% olacağı tahmin edilmektedir.

Anahtar bilgiler

26.9%

Kazanç büyüme oranı

27.2%

EPS büyüme oranı

Healthcare kazanç büyümesi	27.6%
Gelir büyüme oranı	16.3%
Gelecekteki özkaynak getirisi	25.3%
Analist kapsamı	Low
Son güncelleme	24 Oct 2024

Gelecekteki son büyüme güncellemeleri

Thyrocare Technologies Limited (NSE:THYROCARE) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

Jul 26

Revenue Miss: Thyrocare Technologies Limited Fell 10.0% Short Of Analyst Revenue Estimates And Analysts Have Been Revising Their Models

Feb 04

Recent updates

Statutory Profit Doesn't Reflect How Good Thyrocare Technologies' (NSE:THYROCARE) Earnings Are

Oct 31

Thyrocare Technologies Limited (NSE:THYROCARE) Looks Just Right With A 26% Price Jump

Aug 01

Thyrocare Technologies Limited (NSE:THYROCARE) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

Jul 26

A Look At The Fair Value Of Thyrocare Technologies Limited (NSE:THYROCARE)

Jun 12

Getting In Cheap On Thyrocare Technologies Limited (NSE:THYROCARE) Might Be Difficult

Feb 29

Revenue Miss: Thyrocare Technologies Limited Fell 10.0% Short Of Analyst Revenue Estimates And Analysts Have Been Revising Their Models

Feb 04

Here's Why Thyrocare Technologies (NSE:THYROCARE) Can Manage Its Debt Responsibly

Dec 08

Why Thyrocare Technologies' (NSE:THYROCARE) Shaky Earnings Are Just The Beginning Of Its Problems

Nov 08

Thyrocare Technologies (NSE:THYROCARE) Knows How To Allocate Capital Effectively

Mar 23

Thyrocare Technologies Limited (NSE:THYROCARE) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap?

Mar 02

Investors In Thyrocare Technologies Limited (NSE:THYROCARE) Should Consider This, First

Feb 01

Investors Who Bought Thyrocare Technologies (NSE:THYROCARE) Shares A Year Ago Are Now Up 81%

Jan 12

The Chairman & MD of Thyrocare Technologies Limited (NSE:THYROCARE), Velumani Arokiaswamy, Just Bought A Few More Shares

Dec 24

Under The Bonnet, Thyrocare Technologies' (NSE:THYROCARE) Returns Look Impressive

Dec 17

Thyrocare Technologies Limited's (NSE:THYROCARE) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

Nov 30

Analyst Forecasts For Thyrocare Technologies Limited (NSE:THYROCARE) Are Surging Higher

Nov 02

Earnings Update: Thyrocare Technologies Limited (NSE:THYROCARE) Just Reported And Analysts Are Boosting Their Estimates

Nov 01

Kazanç ve Gelir Büyüme Tahminleri

NSEI:THYROCARE - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (INR Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
3/31/2027	9,319	1,647	2,087	2,074	2
3/31/2026	8,062	1,319	1,737	1,733	2
3/31/2025	6,828	998	1,595	1,559	2
9/30/2024	6,233	840	1,648	1,873	N/A
6/30/2024	5,939	776	N/A	N/A	N/A
3/31/2024	5,719	708	1,061	1,676	N/A
12/31/2023	5,535	655	N/A	N/A	N/A
9/30/2023	5,468	648	647	1,418	N/A
6/30/2023	5,338	599	N/A	N/A	N/A
3/31/2023	5,267	645	857	1,293	N/A
12/31/2022	5,214	731	N/A	N/A	N/A
9/30/2022	5,108	800	749	1,001	N/A
6/30/2022	5,520	1,423	N/A	N/A	N/A
3/31/2022	5,889	1,761	756	1,134	N/A
12/31/2021	6,051	1,924	N/A	N/A	N/A
9/30/2021	6,260	2,032	1,249	1,642	N/A
6/30/2021	6,030	1,685	N/A	N/A	N/A
3/31/2021	4,946	1,132	880	1,147	N/A
12/31/2020	4,503	741	N/A	N/A	N/A
9/30/2020	4,178	692	789	1,004	N/A
6/30/2020	3,797	612	N/A	N/A	N/A
3/31/2020	4,343	884	1,580	1,679	N/A
12/31/2019	4,384	1,063	N/A	N/A	N/A
9/30/2019	4,289	990	1,305	1,436	N/A
6/30/2019	4,165	892	N/A	N/A	N/A
3/31/2019	4,039	851	601	1,003	N/A
12/31/2018	3,946	939	N/A	N/A	N/A
9/30/2018	3,822	953	N/A	N/A	N/A
6/30/2018	3,663	947	N/A	N/A	N/A
3/31/2018	3,569	933	N/A	1,070	N/A
12/31/2017	3,493	1,117	N/A	N/A	N/A
9/30/2017	3,359	994	N/A	N/A	N/A
6/30/2017	3,258	759	N/A	N/A	N/A
3/31/2017	3,045	428	N/A	896	N/A
12/31/2016	2,843	659	N/A	N/A	N/A
9/30/2016	2,699	601	N/A	N/A	N/A
6/30/2016	2,535	564	N/A	N/A	N/A
3/31/2016	2,411	518	N/A	678	N/A
3/31/2015	1,835	452	N/A	345	N/A
3/31/2014	1,502	462	N/A	462	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: THYROCARE 'nin tahmini kazanç büyümesi (yıllık 26.9% ) tasarruf oranının ( 6.7% ) üzerindedir.

Kazançlar ve Piyasa: THYROCARE şirketinin kazançlarının (yıllık 26.9% ) Indian pazarından (yıllık 18.1% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Kazançları: THYROCARE şirketinin kazançlarının önümüzdeki 3 yıl içerisinde önemli ölçüde artması bekleniyor.

Gelir ve Pazar: THYROCARE şirketinin gelirinin (yıllık 16.3% ) Indian pazarından (yıllık 10.6% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Geliri: THYROCARE şirketinin gelirinin (yıllık 16.3% ) yıllık 20% oranından daha yavaş büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: THYROCARE 'in Özsermaye Getirisi'nin 3 yıl içinde yüksek olması tahmin ediliyor ( 25.3 %)

Büyüyen şirketleri keşfedin

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2024/12/19 05:28
Gün Sonu Hisse Fiyatı	2024/12/19 00:00
Kazançlar	2024/09/30
Yıllık Kazançlar	2024/03/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Buradan daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları 'da mevcuttur.

Analist Kaynakları

Thyrocare Technologies Limited 12 Bu analistlerden 2, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Alka Katiyar	Batlivala & Karani Securities India Pvt. Ltd.
Rahul Agarwal	CGS International
Kameswari V. S. Chavali	FirstCall Research

Thyrocare Technologies Gelecekteki Büyüme

Future kriter kontrolleri 5/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Price target increased by 9.1% to ₹903

Price target increased by 8.5% to ₹828

Thyrocare Technologies Limited (NSE:THYROCARE) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

Revenue Miss: Thyrocare Technologies Limited Fell 10.0% Short Of Analyst Revenue Estimates And Analysts Have Been Revising Their Models

Price target increased by 7.3% to ₹695

Price target decreased by 7.0% to ₹730

Recent updates

MD, CEO & Chairman recently bought ₹1.1m worth of stock

Statutory Profit Doesn't Reflect How Good Thyrocare Technologies' (NSE:THYROCARE) Earnings Are

Price target increased by 9.1% to ₹903

Second quarter 2025 earnings released: EPS: ₹4.99 (vs ₹3.84 in 2Q 2024)

High number of new directors

Thyrocare Technologies Limited to Report Q2, 2025 Results on Oct 23, 2024

Now 23% overvalued after recent price rise

Price target increased by 8.5% to ₹828

Thyrocare Technologies Limited (BSE:539871) completed the acquisition of Diagnostics and and pathological services business of Virnta Labs Limited from Vimta Labs Limited (BSE:524394) for INR 70 million.

Thyrocare Technologies Limited Announces Cessation of Mr. Neetin Shivajirao Desai as Independent Director as Well as Member of the Respective Committee(s) of the Board

Now 20% overvalued after recent price rise

Thyrocare Technologies Limited Approves Dividend for the Financial Year 2023-24

Thyrocare Technologies Limited Announces Cessation of Gopalkrishna Shivaram Hegde as Independent Director and as Member / Chairman of the Respective Committee

Now 20% overvalued after recent price rise

Upcoming dividend of ₹18.00 per share

Thyrocare Technologies Limited, Annual General Meeting, Aug 23, 2024

Thyrocare Technologies Limited (NSE:THYROCARE) Looks Just Right With A 26% Price Jump

Investor sentiment improves as stock rises 20%

Thyrocare Technologies Limited (BSE:539871) acquired Diagnostic and pathological services business of Polo Labs Private Limited for INR 42.6 million.

Thyrocare Technologies Limited (NSE:THYROCARE) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

Now 23% overvalued after recent price rise

First quarter 2025 earnings released: EPS: ₹4.52 (vs ₹3.26 in 1Q 2024)

Thyrocare Technologies Limited to Report Q1, 2025 Results on Jul 23, 2024

Now 23% overvalued after recent price rise

A Look At The Fair Value Of Thyrocare Technologies Limited (NSE:THYROCARE)

New major risk - Revenue and earnings growth

Thyrocare Technologies Limited Proposes Final Dividend for the Financial Year 2023-24

Thyrocare Technologies Limited to Report Q4, 2024 Results on May 14, 2024

Getting In Cheap On Thyrocare Technologies Limited (NSE:THYROCARE) Might Be Difficult

Thyrocare Technologies Limited (BSE:539871) completed the acquisition of Think Health Diagnostic Private Limited.

Revenue Miss: Thyrocare Technologies Limited Fell 10.0% Short Of Analyst Revenue Estimates And Analysts Have Been Revising Their Models

Third quarter 2024 earnings released: EPS: ₹2.78 (vs ₹1.89 in 3Q 2023)

Thyrocare Technologies Limited to Report Q3, 2024 Results on Feb 01, 2024

Price target increased by 7.3% to ₹695

Here's Why Thyrocare Technologies (NSE:THYROCARE) Can Manage Its Debt Responsibly

Why Thyrocare Technologies' (NSE:THYROCARE) Shaky Earnings Are Just The Beginning Of Its Problems

Second quarter 2024 earnings released: EPS: ₹3.84 (vs ₹3.80 in 2Q 2023)

Thyrocare Technologies Limited to Report Q2, 2024 Results on Oct 31, 2023

MD, CEO & Chairman recently bought ₹4.3m worth of stock

Thyrocare Technologies Limited Appoints Alok Kumar Jagnani as Chief Financial Officer

High number of new directors

Thyrocare Technologies Limited to Report Q1, 2024 Results on Aug 01, 2023

Full year 2023 earnings: EPS and revenues miss analyst expectations

Thyrocare Technologies Limited Accepts Resignation of Sachin Salvi as Chief Financial Officer

Price target decreased by 7.0% to ₹730

Full year 2023 earnings: EPS and revenues miss analyst expectations

Thyrocare Technologies Limited to Report Q4, 2023 Results on May 23, 2023

Thyrocare Technologies Limited Announces Resignation of Vishwas Kulkarni as an Independent Director

Upcoming dividend of ₹18.00 per share at 3.1% yield

MD, CEO & Director recently bought ₹10m worth of stock

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Thyrocare Technologies Limited to Report Q3, 2023 Results on Feb 03, 2023

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Thyrocare Technologies Limited (BSE:539871) agreed to acquire 51% stake in Pulse Hitech Health Services (Ghatkopar) LLP for INR 25.5 million.

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Thyrocare Technologies Limited to Report Q2, 2023 Results on Nov 11, 2022

MD, CEO & Director recently bought ₹16m worth of stock

Thyrocare Technologies Limited Announces Payment of Interim Dividend for the Financial Year 2021-2022

Full year 2022 earnings: EPS and revenues miss analyst expectations

Thyrocare Technologies Limited, Annual General Meeting, Aug 03, 2022

Price target decreased to ₹1,073

Thyrocare Technologies Limited Joins Rahul Guha as Managing Director

Thyrocare Technologies Limited Declares Interim Dividend for the Financial Year 2021-22

Full year 2022 earnings: EPS and revenues miss analyst expectations

Thyrocare Technologies Limited to Report Q4, 2022 Results on Apr 29, 2022

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Thyrocare Technologies Limited Announces Appointment of Rahul Guha as Managing Director

Thyrocare Technologies Limited Appoints Sachin Salvi as Chief Financial Officer

First quarter 2022 earnings released: EPS ₹10.51 (vs ₹0.04 in 1Q 2021)